21 – 30 of 168
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Selection process of measures for core outcome set should utilize the highest methodology level and should be maximally free of bias. Comment on ‘IDQoL, CDLQI and the 45-item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan : a group discussion study’
(
- Contribution to journal › Letter
-
Mark
Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
(
- Contribution to journal › Article
-
Mark
Intervention study to evaluate the importance of information given to patients with contact allergy : a randomized, investigator-blinded clinical trial*
(
- Contribution to journal › Article
-
Mark
Validation of questionnaire algorithm based on repeated open application testing with the constituents of fragrance mix II : the EDEN Fragrance Study
(
- Contribution to journal › Article
-
Mark
Dermatology textbooks in Scandinavia should prepare medical students for ethnic diversity
(
- Contribution to journal › Letter
-
Mark
Skin exposure to scented products used in daily life and fragrance contact allergy in the European general population - The EDEN Fragrance Study
(
- Contribution to journal › Article
-
Mark
Pharmacist recommendations regarding topical steroid use may contradict the standard of care in atopic dermatitis : An international, cross-sectional study
(
- Contribution to journal › Article
- 2020
-
Mark
Oral provocation of patients allergic to sesquiterpene lactones with German chamomile tea to demonstrate possible systemic allergic dermatitis
(
- Contribution to journal › Article
-
Mark
Hidradenitis Suppurativa in Sweden : A Registry-Based Cross-Sectional Study of 13,538 Patients
(
- Contribution to journal › Article
-
Mark
TREatment of ATopic eczema (TREAT) Registry Taskforce : protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
(
- Contribution to journal › Article